scholarly journals Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study

2015 ◽  
Vol 112 (8) ◽  
pp. 1306-1313 ◽  
Author(s):  
U Bork ◽  
N N Rahbari ◽  
S Schölch ◽  
C Reissfelder ◽  
C Kahlert ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prospective Study ◽  
Metastatic Colorectal Cancer ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
A Prospective Study

scholarly journals Baseline and Kinetic Circulating Tumor Cell Counts Are Prognostic Factors in a Prospective Study of Metastatic Colorectal Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 502
Author(s):  
Virgílio Souza e Silva ◽  
Emne Ali Abdallah ◽  
Angelo Borsarelli Carvalho de Brito ◽  
Alexcia Camila Braun ◽  
Milena Shizue Tariki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Drug Resistance ◽  
Prospective Study ◽  
Metastatic Colorectal Cancer ◽  
Clinical Outcomes ◽  
Predictive Biomarkers ◽  
Multi Drug Resistance ◽  
Cell Counts ◽  
Potential Clinical Benefit ◽  
A Prospective Study

The discovery of predictive biomarkers in metastatic colorectal cancer (mCRC) is essential to improve clinical outcomes. Recent data suggest a potential role of circulating tumor cells (CTCs) as prognostic indicators. We conducted a follow-on analysis from a prospective study of consecutive patients with mCRC. CTC analysis was conducted at two timepoints: baseline (CTC1; before starting chemotherapy), and two months after starting treatment (CTC2). CTC isolation/quantification were completed by ISET® (Rarecells, France). CTC expressions of drug resistance-associated proteins were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan–Meier method. Seventy-five patients were enrolled from May 2012 to May 2014. A CTC1 cut-off of >1.5 CTCs/mL was associated with an inferior median OS compared to lower values. A difference of CTC2−CTC1 > 5.5 CTCs/mL was associated with a reduced median PFS. By multivariate analysis, CTC1 > 1.5 CTCs/mL was an independent prognostic factor for worse OS. Multi-drug resistance protein-1 (MRP-1) expression was associated with poor median OS. CTC baseline counts, kinetics, and MRP-1 expression were predictive of clinical outcomes. Larger studies are warranted to explore the potential clinical benefit of treating mCRC patients with targeted therapeutic regimens guided by CTC findings.

scholarly journals Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer

2021 ◽  
Vol 22 (4) ◽  
pp. 2067
Author(s):  
Rhynelle S. Dmello ◽  
Sarah Q. To ◽  
Ashwini L. Chand
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Liver Metastasis ◽  
Metastatic Colorectal Cancer ◽  
Tumour Microenvironment ◽  
Tumour Cells ◽  
Cellular Interactions ◽  
Circulating Tumour Cells ◽  
Therapeutic Targeting ◽  
Colorectal Cancer Patients

Liver metastasis is the primary contributor to the death of patients with colorectal cancer. Despite the overall success of current treatments including targeted therapy, chemotherapy, and immunotherapy combinations in colorectal cancer patients, the prognosis of patients with liver metastasis remains poor. Recent studies have highlighted the importance of the tumour microenvironment and the crosstalk within that determines the fate of circulating tumour cells in distant organs. Understanding the interactions between liver resident cells and tumour cells colonising the liver opens new therapeutic windows for the successful treatment of metastatic colorectal cancer. Here we discuss critical cellular interactions within the tumour microenvironment in primary tumours and in liver metastases that highlight potential therapeutic targets. We also discuss recent therapeutic advances for the treatment of metastatic colorectal cancer.

Circulating tumour cells in non-metastatic breast cancer: a prospective study

2012 ◽  
Vol 13 (7) ◽  
pp. 688-695 ◽  
Author(s):  
Anthony Lucci ◽  
Carolyn S Hall ◽  
Ashutosh K Lodhi ◽  
Anirban Bhattacharyya ◽  
Amber E Anderson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Prospective Study ◽  
Metastatic Breast ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
A Prospective Study

scholarly journals Molecular markers in circulating tumour cells from metastatic colorectal cancer patients

2010 ◽  
Vol 14 (8) ◽  
pp. 2073-2077 ◽  
Author(s):  
Paola Gazzaniga ◽  
Angela Gradilone ◽  
Arianna Petracca ◽  
Chiara Nicolazzo ◽  
Cristina Raimondi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Molecular Markers ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document